PFI	ZEF	R INC	NYSI	E-PFE			R	ecent Rice	34.4	<b>44</b> <sup>P/</sup>	e 19	1 (Trail Med	ing: 28.2 ian: 17.0	RELATIV P/E RATI	<sup>E</sup> 1.0	9 DIV'D YLD	3.5	5%			
TIMELIN	VESS	1 Raised	6/24/16	High: Low:	29.2 20.3	28.6 22.2	27.7 22.2	24.2 14.3	19.0 11.0				32.5 25.3	33.1 27.5	36.5 28.5	35.5 28.3				t Price 2020	
AFET		1 Raised		LEGEN 11	NDS .0 x "Cast	n Flow" p s	sh i		L .	F									2013	2020	64
ECHN		3 Raised	7/1/16	Options:	Yes	e suengui															48
		) = Market) ROJECTI	ONS	1+11+1.		ates recess									սուրի	. II					+40 +32
	Price		Ann'l Total Return	<b>!</b>			1,11,11,11		-			11.11.1 <sup>1.1</sup>	1-1111-L	11-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1		<u> </u> ]]·					24
ligh .ow	50 40	(+45%) (+15%)	13% 8%			• • • • • • • •	•••••	Pa			րությունը հերթեր										+20 +16
-	r Deci	sions		1				· · • • • • • •		••••	••••••••	·********	••••••••••	**************************************	··****	•.•					<u>+</u> 12
Buy	A S 0	<b>) N D J</b> ) 0 0 0								••	••••••	-				••					-8
ptions Sell	0 0 0		1313 0									-						 % то	i )t. retur	 2N 5/16	-6
nstitu	tional 30201	Decisio 5 402015						1												VL ARITH.* INDEX	
o Buy o Sell	842 81	2 943	1003	Percent	12 -		Ilut				ուրիսին	llaut .						1 yr. 3 yr.	3.4 41.2	-3.3 25.5	F
lld's(000)	442140	3 4472083	4595329	traded	6												0047	5 yr.	93.5	51.1	
4.68	<b>200</b> 1			<b>2004</b> 7.03	2005 6.97	<b>2006</b> 6.79	<b>2007</b> 7.16	2008 7.16	<b>2009</b> 6.20			<b>2012</b> 8.11	<b>2013</b> 8.06	<b>2014</b> 7.89	<b>2015</b> 7.91	2016 8.65	2017 9.15		<u>-UE LINE P</u> or sh	UB. LLC	<u>19-2</u> 10.
1.18	1.5			2.84	2.80	2.85	3.03	1.94	1.66				2.77	2.32	1.96	2.65	2.85		Flow" per	sh	3.
1.02	1.3			2.12	2.02	2.06	2.20	1.18	1.23			1.26	1.65	1.41	1.11	1.80	2.00		js per sh		2.
.36 .35	.4			.68 .35	.76	.96 .29	1.16	1.28	.80		72 .80 19 .22		.96	1.04	1.12	1.20 .25	1.28 .25		Decl'd per pending p		1.
2.55	2.9	1 3.24		9.10	8.88	9.98	9.60	8.52	11.1				11.92	11.33	10.48	10.35	10.70	Book V	alue per s	hC	12.
314.0 40.7	6277. 31.			7473.0	7361.0	7124.0	6761.0 11.5	6746.0 16.4	8070.0				6399.0 17.6	6291.0 21.5	6175.0 30.3	6000.00 Bold fig	5900.00 ures are		on Shs Ou n'I P/E Rat	•	5700. 17
2.65	1.6	3 1.25	5 1.04	.82	.68	.67	.61	.99	.8	5 1.0		1.17	.99	1.13	1.54	Value	Line	-	e P/E Ratio		1.
.9%	1.19			2.1%	3.0%	3.7%	4.6%	6.6%	5.1%	4.3	% 4.1%	3.8%	3.3%	3.4%	3.3%	estin	nates	Avg An	n'l Div'd Y	ïeld	3.3
			as of 3/31 Due in 5 \		l3 mill	48371 49.1%	48404 47.8%	48296 45.9%	50009 46.2%			58986 52.2%	51584 53.1%	49605 46.5%	48851 44.8%	52000 46.0%	54000 50.0%	,			580 53.0
	t \$2782		LT Interes	st \$1200 i	mill.	5293.0	5200.0	45.9% 5090.0	40.2%	_	_	_	6410.0	5537.0	5157.0	40.0%			ng Margin iation (\$m		53.0
				(31% o	f Capíl)	14984	15267	8026.0	8621.0			_	11341	9088.0	6949.0	10800	11800	Net Pro	fit (\$mill)	,	156
						21.0% 31.5%	17.0%	20.3%			21.2%	27.4%	25.5% 18.3%	22.2%	25.0% 20.8%	25.0% 21.9%		Tax Rate fit Margin		25.0 27.0	
						25014	16067	2444			32796	32878	36071	14405	13000			g Cap'l (\$r	nill)	300	
ensio	n Asse	ts-12/15 \$	619.6 bill. (	Oblig. \$2	5.5 Dill.	5546.0	7314.0	7963.0	43193			31036	30462	31541	28818	27000	27000		erm Debt (		250
Commo	on Stor	<b>k</b> 6 064 8	49,361 sh	19		71358	65010 21.4%	57556 12.6%	90014 6.8%			81260 9.0%	76307	71301 9.4%	64720 8.0%	62000 13.0%	14.0%		uity (\$mill on Total C		720
s of 5/	9/16		,			21.0%	23.5%	13.9%	9.6%	9.4	% 10.6%	11.7%	14.9%	12.7%	10.7%	17.5%	18.5%	Return	on Shr. Ec	uity	22.0
CURRENT POSITION 2014 2015 3/31/16 46% 52						11.2% 52%	NMF 106%	3.4%			3.6% 69%	6.2% 58%	3.5% 73%	NMF 100%	6.0% 67%	6.5% 64%		d to Com ds to Net I	•	9.5 55	
(\$MI Cash A	LL.)			23290	19443						sed, globa								d Pharma		
Receiva			8669 5663	8176 7513	9033 7578	cal con	npany en	gaging i	n the dis	scovery,	developm	ent, manu	facture,	Top-sel	ling prodi	ucts '15:	Prevnar	, Lyrica,	Enbrel, a	and <i>Lipit</i>	òr. Ha
Other	t Asset	_	7248	4825 43804	5244 41298						lio include: sumer hea								n 1% of ( reet, 5.1%		
Accts F	Payable		3440	3620	3125						gments: ( , Oncology								: 235 Eas		
Debt D Dther			13050		14064						nergei										
					28735	lerg	an w	vas t	ermi	inate	d sho	rtly	after	sion	coul	dັcoı	ne in	ı late	e 2016	6. Pfiz	er
f change	L RAT	10 Yr:	s. 5 Yı		'19-'21						<b>pres</b>										
"Cash Flow" -1.0% 4.5% 7.5% concer						cern that the deal would not go								Global Established Pharmaceuticals business (GEP) from rest of the group (GIP)							
Earnings -3.5% 4.0% 12.0% through Dividends 4.5% 2.0% 6.5%							due to mounting government							While compelling arguments have bee made on both sides, and it could really g							
look V	1				1	the	U.Š. '	Treas	ury	unvei	led a	new s	set of	eithe	r way	, the	Stree				
Cal- ndar			' SALES (\$ 1 ) Sep.30		Full Year	rules	s gea s Tha	red	towa	rd d	iscoura ilted ii	iging 1 a m	such	in fa	vor of t.auai	a spli rter	t.	ilte	woro	sti	on
2013 2014	12410		12643		51584	term	inatio	on of t	he m	ergei	:			Pfize	r easi	ily be	eat co	nsens	sus ex	pecta	tion
2015	11353 10864	11853		14047	49605 48851						ny set e rece										
2016 2017	13005 13000		12600 13500		52000 54000	plet	ed ao	cquis	ition	of	Anaco	r. Ŏn	May	comp	any i	now o	expect	t <b>s 20</b>	16 GA	4AP	ear
Cal-			PER SHAR		Full						plans										
ndar	Mar.3	1 Jun.30	) Sep.30	Dec.31	Year						asset crisabo										
2013 2014	.36 .36		.39 .42	.40 .19	1.65 1.41	stere	oidal t	topica	l PD	E4 in	hibito	' with	anti-	The	adjus	ted r	ange	was	bump	bed u	
2015	.38	.42	.34	d.03	1.11						is cu reatme										bee
2016 2017	.49 .50		.47 .55	.38 .45	1.80 2.00	to n	iodera	ite at	opic	derm	atitis,	more	com-	rein	stated	l at	1 (Hi	ighes	t). We	e con	tinı
Cal-			VIDENDS P		Full						a. Pfiz exceed										
ndar			Sep.30		Year	Man	agem	ent d	oes n	ot ex	cpect t	he tra	nsac-	ceuti	cal in	ıdustr	y. An	ı abo	ve-ave	rage	div
2012 2013	.22		.22 .24	.22 .24	.88 .96						ilts, b										
2014	.26	.26	.26	.26	1.04						utive eal was							re huo	viues	a 000	st
2015 2016	.28 .30		.28	.28	1.12		une 24					r			ael Ra				Ju	ly 8,	201
) Dilute	ed earn	ings (GAA	P). May r	not sum d		udes int						arnings fr	om adjus	sted in 20	08.		mpany's ck's Prio		al Streng	th	A++ 95
e Aug	ust 2n	d. <b>(B)</b> Div	. Next ear	aid in ea	rly   4/03	, include	d from 2	nd qtr. (	F) Wye	th acqd						Pri	ce Grow	th Persis	stence		60
ar., Jur	n, Sep.,	Dec.■ Di	v'd reinve								eliable and						nings Pi				70

to change in share count. Next earnings report [\$14.35/sf. (U) in millions. (E) Pharmacia acqd. due August 2nd. (B) Dividends paid in early [4/03, included from 2nd qtr. (F) Wyeth acqd. Mar., Jun, Sep., Dec.= Div'd reinvest. plan. (C) [10/09, included from 4th qtr. (G) Switched to ] © 2016 Value Line, Inc. All rights reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. THE PUBLISHER IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN. This publication is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, resold, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product.

To subscribe call 1-800-VALUELINE